Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors
MetadataShow full item record
CitationTomasetti, Cristian, George D Demetri, and Giovanni Parmigiani. 2013. “Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.” F1000Research 2 (1): 152. doi:10.12688/f1000research.2-152.v1. http://dx.doi.org/10.12688/f1000research.2-152.v1.
AbstractBackground: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. Methods and results: By combining clinical and experimental observations with mathematical formulas we estimate that, in advanced GIST, the genetic changes responsible for resistance are generally already present at disease detection. Conclusion: This result has relevant clinical implications by providing support for the exploration of combination therapies.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879540